focus -WSS

focus

author：hotspot 2025-10-01 21:36:15 - browse：5

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Study: Adult vaccinations pay for themselves in societal benefits

leisure time

focus

WSS

Letters to First Opinion on caregivers, digital health, and more

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Shifting the focus from loneliness to social health

Brain worms: The science behind RFK Jr.'s parasitic infection

Making AI in medicine accessible to smaller, and rural hospitals

Bird flu outbreak in cows is latest avian flu curveball

focus

focus

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Researchers on aging grapple with how to calculate biological age

In Memoriam: Notable people who died in 2023

H5N1 bird flu: what we're starting to learn about infection in cows

What does generative AI mean for health care? We asked experts

Brain worms: The science behind RFK Jr.'s parasitic infection

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How to improve immunocompromised access to mAb treatments

At least 13 dead in Texas as scorching temps continue

Use wet bulb globe temperature, not heat index, to protect workers

focus

Telehealth startups turn to complex chronic diseases

BMI, flaws aside, is found to be useful estimate of body fat in youth

H5N1 bird flu: what we're starting to learn about infection in cows

Let's speed up science by embracing open access publishing

Woman returns to dialysis after doctors remove transplanted pig kidney

Elevance, private equity launch primary care company

explore

leisure time

focus

focus